Financials data is unavailable for this security.
View more
Year on year Albert David Ltd grew revenues 6.12% from 3.42bn to 3.62bn while net income improved 108.49% from 361.75m to 754.20m.
| Gross margin | 65.26% |
|---|---|
| Net profit margin | 19.67% |
| Operating margin | 7.78% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Albert David Ltd increased its cash reserves by 276.29%, or 39.94m. The company earned 455.02m from its operations for a Cash Flow Margin of 12.55%. In addition the company used 332.48m on investing activities and also paid 82.70m in financing cash flows.
| Cash flow per share | 135.86 |
|---|---|
| Price/Cash flow per share | 10.74 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 27.78% and 108.49%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 1.67% |
|---|---|
| Div growth rate (5 year) | 13.90% |
| Payout ratio (TTM) | 9.27% |
| EPS growth(5 years) | 33.59 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 22.22 |
More ▼
